Methods for treating breast cancer and for identifying breast cancer antigens
Disclosed herein are isolated compositions including at least 2 of mutant peptides selected from the group consisting of SEQ ID NOS: 1-149, or polypeptides comprising the mutant peptides; wherein the composition comprises mutant peptides encoded by 2 or more genes. Also disclosed are methods for personalized treatment of breast cancer involving creating a peptide array of mutant peptides comprising the mutations in protein-encoding regions of the high-frequency cancer genes or the exome in a subject and screening the peptide array with a biological sample from the subject to detect antibodies in the biological sample that bind to the array, to detect antigenic targets for therapy in treating the subject.
1. An isolated composition, comprising at least 25 mutant peptides selected from the group consisting of SEQ ID NOS: 1-82,84-91, and 93-149, or polypeptides comprising the mutant peptides; wherein the composition comprises mutant peptides encoded by 10 or more genes and wherein the mutant peptides are fluorescently labeled.
2. The isolated composition of claim 1 , wherein the composition further comprises one or more wild type peptides corresponding to the mutant peptides, or polypeptides comprising the wild type peptides.
3. The isolated composition of claim 2 , wherein the composition further comprises 25 or more wild type peptide counterparts to the mutant peptides, or polypeptides comprising the wild type peptides.
4. The isolated composition of claim 2 , wherein the total number of mutant and wild type peptides, or polypeptides comprising the mutant and wild type peptides, is 100,000 or less.
5. The isolated composition of claim 2 , wherein the total number of mutant and wild type peptides, or polypeptides comprising the mutant and wild type peptides, is 1000 or less.
6. The isolated composition of claim 1 , wherein the mutant peptides are immobilized on the surface of a solid support.